{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T03:38:29Z","timestamp":1792899509883,"version":"4.5.0"},"reference-count":80,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T00:00:00Z","timestamp":1702339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Jameel Fund for Infectious Disease Research and Innovation in Saudi Arabia","award":["(8-6)2120191"],"award-info":[{"award-number":["(8-6)2120191"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and the Middle East respiratory syndrome coronavirus (MERS-CoV) are highly pathogenic human coronaviruses (CoVs). Anti-CoVs mAbs and vaccines may be effective, but the emergence of neutralization escape variants is inevitable. Angiotensin-converting enzyme 2 and dipeptidyl peptidase 4 enzyme are the getaway receptors for SARS-CoV-2 and MERS-CoV, respectively. Thus, we reformatted these receptors as Fc-fusion decoy receptors. Then, we tested them in parallel with anti-SARS-CoV (ab1-IgG) and anti-MERS-CoV (M336-IgG) mAbs against several variants using pseudovirus neutralization assay. The generated Fc-based decoy receptors exhibited a strong inhibitory effect against all pseudotyped CoVs. Results showed that although mAbs can be effective antiviral drugs, they might rapidly lose their efficacy against highly mutated viruses. We suggest that receptor traps can be engineered as Fc-fusion proteins for highly mutating viruses with known entry receptors, for a faster and effective therapeutic response even against virus harboring antibodies escape mutations.<\/jats:p>","DOI":"10.1093\/abt\/tbad030","type":"journal-article","created":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T08:41:43Z","timestamp":1701938503000},"page":"53-66","source":"Crossref","is-referenced-by-count":9,"title":["ACE2-Fc and DPP4-Fc decoy receptors against SARS-CoV-2 and MERS-CoV variants: a quick therapeutic option for current and future coronaviruses outbreaks"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3716-0019","authenticated-orcid":false,"given":"Mohamed A","family":"Alfaleh","sequence":"first","affiliation":[{"name":"Department of Pharmaceutics , Faculty of Pharmacy, , Jeddah 21859 ,","place":["Saudi Arabia"]},{"name":"King Abdulaziz University , Faculty of Pharmacy, , Jeddah 21859 ,","place":["Saudi Arabia"]},{"name":"Vaccines and Immunotherapy Unit , King Fahd Medical Research Center, , Jeddah 21859 ,","place":["Saudi Arabia"]},{"name":"King Abdulaziz University , King Fahd Medical Research Center, , Jeddah 21859 ,","place":["Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem M","family":"Alsulaiman","sequence":"additional","affiliation":[{"name":"Vaccines and Immunotherapy Unit , King Fahd Medical Research Center, , Jeddah 21859 ,","place":["Saudi Arabia"]},{"name":"King Abdulaziz University , King Fahd Medical Research Center, , Jeddah 21859 ,","place":["Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah A","family":"Almahboub","sequence":"additional","affiliation":[{"name":"Vaccines and Immunotherapy Unit , King Fahd Medical Research Center, , Jeddah 21859 ,","place":["Saudi Arabia"]},{"name":"King Abdulaziz University , King Fahd Medical Research Center, , Jeddah 21859 ,","place":["Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leena","family":"Nezamuldeen","sequence":"additional","affiliation":[{"name":"Vaccines and Immunotherapy Unit , King Fahd Medical Research Center, , Jeddah 21859 ,","place":["Saudi Arabia"]},{"name":"King Abdulaziz University , King Fahd Medical Research Center, , Jeddah 21859 ,","place":["Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayat","family":"Zawawi","sequence":"additional","affiliation":[{"name":"Vaccines and Immunotherapy Unit , King Fahd Medical Research Center, , Jeddah 21859 ,","place":["Saudi Arabia"]},{"name":"King Abdulaziz University , King Fahd Medical Research Center, , Jeddah 21859 ,","place":["Saudi Arabia"]},{"name":"Department of Medical Laboratory Sciences , Faculty of Applied Medical Sciences, , Jeddah 21859 ,","place":["Saudi Arabia"]},{"name":"King Abdulaziz University , Faculty of Applied Medical Sciences, , Jeddah 21859 ,","place":["Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najwa D","family":"Aljehani","sequence":"additional","affiliation":[{"name":"Vaccines and Immunotherapy Unit , King Fahd Medical Research Center, , Jeddah 21859 ,","place":["Saudi Arabia"]},{"name":"King Abdulaziz University , King Fahd Medical Research Center, , Jeddah 21859 ,","place":["Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Yasir","sequence":"additional","affiliation":[{"name":"Vaccines and Immunotherapy Unit , King Fahd Medical Research Center, , Jeddah 21859 ,","place":["Saudi Arabia"]},{"name":"King Abdulaziz University , King Fahd Medical Research Center, , Jeddah 21859 ,","place":["Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rwaa H","family":"Abdulal","sequence":"additional","affiliation":[{"name":"Vaccines and Immunotherapy Unit , King Fahd Medical Research Center, , Jeddah 21859 ,","place":["Saudi Arabia"]},{"name":"King Abdulaziz University , King Fahd Medical Research Center, , Jeddah 21859 ,","place":["Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Alkhaldi","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics , Faculty of Pharmacy, , Jeddah 21859 ,","place":["Saudi Arabia"]},{"name":"King Abdulaziz University , Faculty of Pharmacy, , Jeddah 21859 ,","place":["Saudi Arabia"]},{"name":"Vaccines and Immunotherapy Unit , King Fahd Medical Research Center, , Jeddah 21859 ,","place":["Saudi Arabia"]},{"name":"King Abdulaziz University , King Fahd Medical Research Center, , Jeddah 21859 ,","place":["Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assala","family":"Helal","sequence":"additional","affiliation":[{"name":"Vaccines and Immunotherapy Unit , King Fahd Medical Research Center, , Jeddah 21859 ,","place":["Saudi Arabia"]},{"name":"King Abdulaziz University , King Fahd Medical Research Center, , Jeddah 21859 ,","place":["Saudi Arabia"]},{"name":"Department of Pharmacology and Toxicology , Faculty of Pharmacy, , Jeddah 21859 ,","place":["Saudi Arabia"]},{"name":"King Abdulaziz University , Faculty of Pharmacy, , Jeddah 21859 ,","place":["Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sawsan S","family":"Alamri","sequence":"additional","affiliation":[{"name":"Vaccines and Immunotherapy Unit , King Fahd Medical Research Center, , Jeddah 21859 ,","place":["Saudi Arabia"]},{"name":"King Abdulaziz University , King Fahd Medical Research Center, , Jeddah 21859 ,","place":["Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Malki","sequence":"additional","affiliation":[{"name":"Vaccines and Immunotherapy Unit , King Fahd Medical Research Center, , Jeddah 21859 ,","place":["Saudi Arabia"]},{"name":"King Abdulaziz University , King Fahd Medical Research Center, , Jeddah 21859 ,","place":["Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rowa Y","family":"Alhabbab","sequence":"additional","affiliation":[{"name":"Vaccines and Immunotherapy Unit , King Fahd Medical Research Center, , Jeddah 21859 ,","place":["Saudi Arabia"]},{"name":"King Abdulaziz University , King Fahd Medical Research Center, , Jeddah 21859 ,","place":["Saudi Arabia"]},{"name":"Department of Medical Laboratory Sciences , Faculty of Applied Medical Sciences, , Jeddah 21859 ,","place":["Saudi Arabia"]},{"name":"King Abdulaziz University , Faculty of Applied Medical Sciences, , Jeddah 21859 ,","place":["Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Turki S","family":"Abujamel","sequence":"additional","affiliation":[{"name":"Vaccines and Immunotherapy Unit , King Fahd Medical Research Center, , Jeddah 21859 ,","place":["Saudi Arabia"]},{"name":"King Abdulaziz University , King Fahd Medical Research Center, , Jeddah 21859 ,","place":["Saudi Arabia"]},{"name":"Department of Medical Laboratory Sciences , Faculty of Applied Medical Sciences, , Jeddah 21859 ,","place":["Saudi Arabia"]},{"name":"King Abdulaziz University , Faculty of Applied Medical Sciences, , Jeddah 21859 ,","place":["Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil A","family":"Alhakamy","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics , Faculty of Pharmacy, , Jeddah 21859 ,","place":["Saudi Arabia"]},{"name":"King Abdulaziz University , Faculty of Pharmacy, , Jeddah 21859 ,","place":["Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisha","family":"Alnami","sequence":"additional","affiliation":[{"name":"Vaccines and Immunotherapy Unit , King Fahd Medical Research Center, , Jeddah 21859 ,","place":["Saudi Arabia"]},{"name":"King Abdulaziz University , King Fahd Medical Research Center, , Jeddah 21859 ,","place":["Saudi Arabia"]},{"name":"Department of Pharmacology and Toxicology , Faculty of Pharmacy, , Jeddah 21859 ,","place":["Saudi Arabia"]},{"name":"King Abdulaziz University , Faculty of Pharmacy, , Jeddah 21859 ,","place":["Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Algaissi","sequence":"additional","affiliation":[{"name":"Vaccines and Immunotherapy Unit , King Fahd Medical Research Center, , Jeddah 21859 ,","place":["Saudi Arabia"]},{"name":"King Abdulaziz University , King Fahd Medical Research Center, , Jeddah 21859 ,","place":["Saudi Arabia"]},{"name":"Department of Medical Laboratories Technology , College of Applied Medical Sciences, , Jazan ,","place":["Saudi Arabia"]},{"name":"Jazan University , College of Applied Medical Sciences, , Jazan ,","place":["Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen","family":"Hassanain","sequence":"additional","affiliation":[{"name":"Department of Surgery , Faculty of Medicine, , Riyadh 11451 ,","place":["Saudi Arabia"]},{"name":"King Saud University , Faculty of Medicine, , Riyadh 11451 ,","place":["Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwar M","family":"Hashem","sequence":"additional","affiliation":[{"name":"Vaccines and Immunotherapy Unit , King Fahd Medical Research Center, , Jeddah 21859 ,","place":["Saudi Arabia"]},{"name":"King Abdulaziz University , King Fahd Medical Research Center, , Jeddah 21859 ,","place":["Saudi Arabia"]},{"name":"Department of Medical Microbiology and Parasitology , Faculty of Medicine, , Jeddah 21859 ,","place":["Saudi Arabia"]},{"name":"King Abdulaziz University , Faculty of Medicine, , Jeddah 21859 ,","place":["Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,12,12]]},"reference":[{"key":"2026050905114633200_ref1","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1093\/ije\/dyaa033","article-title":"The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned?","volume":"49","author":"Peeri","year":"2020","journal-title":"Int J Epidemiol"},{"key":"2026050905114633200_ref2","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.chom.2021.01.014","article-title":"Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization","volume":"29","author":"Liu","year":"2021","journal-title":"Cell Host Microbe"},{"key":"2026050905114633200_ref3","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.chom.2020.11.007","article-title":"Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition","volume":"29","author":"Greaney","year":"2021","journal-title":"Cell Host Microbe"},{"key":"2026050905114633200_ref4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-021-00784-w","article-title":"Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection","volume":"29","author":"Hwang","year":"2022","journal-title":"J Biomed Sci"},{"key":"2026050905114633200_ref5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1515\/dx-2021-0149","article-title":"Updated picture of SARS-CoV-2 variants and mutations","volume":"9","author":"Lippi","year":"2021","journal-title":"Diagnosis (Berl)"},{"key":"2026050905114633200_ref6","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/S0140-6736(19)33221-0","article-title":"Middle East respiratory syndrome","volume":"395","author":"Memish","year":"2020","journal-title":"Lancet"},{"key":"2026050905114633200_ref7","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1211721","article-title":"Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia","volume":"367","author":"Zaki","year":"2012","journal-title":"N Engl J Med"},{"key":"2026050905114633200_ref8","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1080\/22221751.2019.1624482","article-title":"Antibodies and vaccines against Middle East respiratory syndrome coronavirus","volume":"8","author":"Xu","year":"2019","journal-title":"Emerg Microbes Infect"},{"key":"2026050905114633200_ref9","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"2026050905114633200_ref10","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/nature02145","article-title":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus","volume":"426","author":"Li","year":"2003","journal-title":"Nature"},{"key":"2026050905114633200_ref11","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.cell.2020.04.004","article-title":"Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2","volume":"181","author":"Monteil","year":"2020","journal-title":"Cell"},{"key":"2026050905114633200_ref12","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1126\/science.abc0870","article-title":"Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2","volume":"369","author":"Chan","year":"2020","journal-title":"Science"},{"key":"2026050905114633200_ref13","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25225392","article-title":"A novel purification procedure for active recombinant human DPP4 and the inability of DPP4 to bind SARS-CoV-2","volume":"25","author":"Xi","year":"2020","journal-title":"Molecules"},{"key":"2026050905114633200_ref14","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/infdis\/jiy574","article-title":"Elevated human dipeptidyl peptidase 4 expression reduces the susceptibility of hDPP4 transgenic mice to Middle East respiratory syndrome coronavirus infection and disease","volume":"219","author":"Algaissi","year":"2019","journal-title":"J Infect Dis"},{"key":"2026050905114633200_ref15","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/cr.2013.92","article-title":"Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4","volume":"23","author":"Wang","year":"2013","journal-title":"Cell Res"},{"key":"2026050905114633200_ref16","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nature12005","article-title":"Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC","volume":"495","author":"Raj","year":"2013","journal-title":"Nature"},{"key":"2026050905114633200_ref17","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/nchembio.1636","article-title":"An engineered Axl \u2018decoy receptor\u2019 effectively silences the Gas6-Axl signaling axis","volume":"10","author":"Kariolis","year":"2014","journal-title":"Nat Chem Biol"},{"key":"2026050905114633200_ref18","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.copbio.2009.10.010","article-title":"Receptor-Fc fusion therapeutics, traps, and MIMETIBODY technology","volume":"20","author":"Huang","year":"2009","journal-title":"Curr Opin Biotechnol"},{"key":"2026050905114633200_ref19","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/jssc.202000765","article-title":"Therapeutic Fc-fusion proteins: current analytical strategies","volume":"44","author":"Duivelshof","year":"2021","journal-title":"J Sep Sci"},{"key":"2026050905114633200_ref20","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.virol.2014.02.005","article-title":"Phagocytic cells contribute to the antibody-mediated elimination of pulmonary-infected SARS coronavirus","volume":"454-455","author":"Yasui","year":"2014","journal-title":"Virology"},{"key":"2026050905114633200_ref21","doi-asserted-by":"crossref","first-page":"72","DOI":"10.12688\/f1000research.22211.2","article-title":"Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China","volume":"9","author":"Kruse","year":"2020","journal-title":"F1000Res"},{"key":"2026050905114633200_ref22","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.889372","article-title":"Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2","volume":"13","author":"Wines","year":"2022","journal-title":"Front Immunol"},{"key":"2026050905114633200_ref23","doi-asserted-by":"crossref","first-page":"9763","DOI":"10.1073\/pnas.0403235101","article-title":"Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway","volume":"101","author":"Bitonti","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026050905114633200_ref24","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40259-015-0133-6","article-title":"Fusion proteins for half-life extension of biologics as a strategy to make biobetters","volume":"29","author":"Strohl","year":"2015","journal-title":"BioDrugs"},{"key":"2026050905114633200_ref25","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1080\/19420862.2015.1113360","article-title":"Pharmacokinetic properties of IgG and various Fc fusion proteins in mice","volume":"8","author":"Unverdorben","year":"2016","journal-title":"MAbs"},{"key":"2026050905114633200_ref26","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1002\/emmm.201201379","article-title":"Fc-fusion proteins: new developments and future perspectives","volume":"4","author":"Czajkowsky","year":"2012","journal-title":"EMBO Mol Med"},{"key":"2026050905114633200_ref27","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.kint.2018.01.029","article-title":"Novel ACE2-Fc chimeric fusion provides long-lasting hypertension control and organ protection in mouse models of systemic renin angiotensin system activation","volume":"94","author":"Liu","year":"2018","journal-title":"Kidney Int"},{"key":"2026050905114633200_ref28","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1038\/s41467-020-16048-4","article-title":"Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig","volume":"11","author":"Lei","year":"2020","journal-title":"Nat Commun"},{"key":"2026050905114633200_ref29","doi-asserted-by":"crossref","first-page":"28046","DOI":"10.1073\/pnas.2016093117","article-title":"Engineered ACE2 receptor traps potently neutralize SARS-CoV-2","volume":"117","author":"Glasgow","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026050905114633200_ref30","doi-asserted-by":"crossref","first-page":"29832","DOI":"10.1073\/pnas.2010197117","article-title":"Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection","volume":"117","author":"Li","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026050905114633200_ref31","doi-asserted-by":"crossref","first-page":"7796","DOI":"10.1128\/JVI.00912-14","article-title":"Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies","volume":"88","author":"Ying","year":"2014","journal-title":"J Virol"},{"key":"2026050905114633200_ref32","doi-asserted-by":"crossref","first-page":"D482","DOI":"10.1093\/nar\/gkw1065","article-title":"Virus Variation Resource - improved response to emergent viral outbreaks","volume":"45","author":"Hatcher","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"2026050905114633200_ref33","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/molbev\/mst010","article-title":"MAFFT multiple sequence alignment software version 7: improvements in performance and usability","volume":"30","author":"Katoh","year":"2013","journal-title":"Mol Biol Evol"},{"key":"2026050905114633200_ref34","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/jcc.20084","article-title":"UCSF Chimera\u2014a visualization system for exploratory research and analysis","volume":"25","author":"Pettersen","year":"2004","journal-title":"J Comput Chem"},{"key":"2026050905114633200_ref35","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.3389\/fmicb.2020.02020","article-title":"Evaluation of neutralizing antibodies against highly pathogenic coronaviruses: a detailed protocol for a rapid evaluation of neutralizing antibodies using vesicular stomatitis virus pseudovirus-based assay","volume":"11","author":"Almahboub","year":"2020","journal-title":"Front Microbiol"},{"key":"2026050905114633200_ref36","doi-asserted-by":"crossref","DOI":"10.3390\/v9090255","article-title":"Identification of a novel inhibitor against Middle East respiratory syndrome coronavirus","volume":"9","author":"Sun","year":"2017","journal-title":"Viruses"},{"key":"2026050905114633200_ref37","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1056\/NEJMc2100362","article-title":"New SARS-CoV-2 variants - clinical, public health, and vaccine implications","volume":"384","author":"Abdool Karim","year":"2021","journal-title":"N Engl J Med"},{"key":"2026050905114633200_ref38","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s41586-021-03944-y","article-title":"SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion","volume":"599","author":"Mlcochova","year":"2021","journal-title":"Nature"},{"key":"2026050905114633200_ref39","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1016\/j.cell.2021.02.042","article-title":"SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape","volume":"184","author":"Li","year":"2021","journal-title":"Cell"},{"key":"2026050905114633200_ref40","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1016\/j.cell.2021.02.037","article-title":"Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera","volume":"184","author":"Zhou","year":"2021","journal-title":"Cell"},{"key":"2026050905114633200_ref41","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41423-021-00836-z","article-title":"Increased immune escape of the new SARS-CoV-2 variant of concern Omicron","volume":"19","author":"Hu","year":"2022","journal-title":"Cell Mol Immunol"},{"key":"2026050905114633200_ref42","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1016\/j.cell.2021.06.020","article-title":"Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum","volume":"184","author":"Liu","year":"2021","journal-title":"Cell"},{"key":"2026050905114633200_ref43","doi-asserted-by":"crossref","first-page":"1993768","DOI":"10.1080\/19420862.2021.1993768","article-title":"Impact of IgG subclass on molecular properties of monoclonal antibodies","volume":"13","author":"Tang","year":"2021","journal-title":"MAbs"},{"key":"2026050905114633200_ref44","doi-asserted-by":"crossref","first-page":"2191301","DOI":"10.1080\/19420862.2023.2191301","article-title":"Trends in industrialization of biotherapeutics: a survey of product characteristics of 89 antibody-based biotherapeutics","volume":"15","author":"Martin","year":"2023","journal-title":"MAbs"},{"key":"2026050905114633200_ref45","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119523","article-title":"Protein aggregation and immunogenicity of biotherapeutics","volume":"585","author":"Pham","year":"2020","journal-title":"Int J Pharm"},{"key":"2026050905114633200_ref46","doi-asserted-by":"crossref","first-page":"2205540","DOI":"10.1080\/19420862.2023.2205540","article-title":"A systematic review of commercial high concentration antibody drug products approved in the US: formulation composition, dosage form design and primary packaging considerations","volume":"15","author":"Ghosh","year":"2023","journal-title":"MAbs"},{"key":"2026050905114633200_ref47","doi-asserted-by":"crossref","first-page":"2057832","DOI":"10.1080\/19420862.2022.2057832","article-title":"David versus Goliath: ACE2-Fc receptor traps as potential SARS-CoV-2 inhibitors","volume":"14","author":"Alfaleh","year":"2022","journal-title":"MAbs"},{"key":"2026050905114633200_ref48","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1093\/infdis\/jiw080","article-title":"Prophylaxis with a Middle East Respiratory Syndrome Coronavirus (MERS-CoV)-specific human monoclonal antibody protects rabbits from MERS-CoV infection","volume":"213","author":"Houser","year":"2016","journal-title":"J Infect Dis"},{"key":"2026050905114633200_ref49","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms9223","article-title":"Junctional and allele-specific residues are critical for MERS-CoV neutralization by an exceptionally potent germline-like antibody","volume":"6","author":"Ying","year":"2015","journal-title":"Nat Commun"},{"key":"2026050905114633200_ref50","article-title":"SARS-COV-2 variants: differences and potential of immune evasion","volume":"11","author":"Hirabara","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"2026050905114633200_ref51","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.110156","article-title":"Structural analysis of receptor binding domain mutations in SARS-CoV-2 variants of concern that modulate ACE2 and antibody binding","volume":"37","author":"Mannar","year":"2021","journal-title":"Cell Rep"},{"key":"2026050905114633200_ref52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3001237","article-title":"Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies","volume":"19","author":"Zhu","year":"2021","journal-title":"PLoS Biol"},{"key":"2026050905114633200_ref53","doi-asserted-by":"crossref","DOI":"10.1101\/2021.03.22.436481","article-title":"Neutralization of European, South African, and United States SARS-CoV-2 mutants by a human antibody and antibody domains","author":"Sun","year":"2021"},{"key":"2026050905114633200_ref54","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00685-21","article-title":"Characterization of a novel ACE2-based therapeutic with enhanced rather than reduced activity against SARS-CoV-2 variants","volume":"95","author":"Ferrari","year":"2021","journal-title":"J Virol"},{"key":"2026050905114633200_ref55","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.cell.2022.01.001","article-title":"Receptor binding and complex structures of human ACE2 to spike RBD from omicron and delta SARS-CoV-2","volume":"185","author":"Han","year":"2022","journal-title":"Cell"},{"key":"2026050905114633200_ref56","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1126\/science.abn7760","article-title":"SARS-CoV-2 Omicron variant: antibody evasion and cryo-EM structure of spike protein-ACE2 complex","volume":"375","author":"Mannar","year":"2022","journal-title":"Science"},{"key":"2026050905114633200_ref57","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1038\/s41467-022-28324-6","article-title":"Structural and biochemical rationale for enhanced spike protein fitness in delta and kappa SARS-CoV-2 variants","volume":"13","author":"Saville","year":"2022","journal-title":"Nat Commun"},{"key":"2026050905114633200_ref58","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.cell.2020.08.012","article-title":"Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding","volume":"182","author":"Starr","year":"2020","journal-title":"Cell"},{"key":"2026050905114633200_ref59","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1016\/j.cell.2021.05.031","article-title":"Binding and molecular basis of the bat coronavirus RaTG13 virus to ACE2 in humans and other species","volume":"184","author":"Liu","year":"2021","journal-title":"Cell"},{"key":"2026050905114633200_ref60","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1038\/s41564-021-00954-4","article-title":"SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution","volume":"6","author":"Zahradnik","year":"2021","journal-title":"Nat Microbiol"},{"key":"2026050905114633200_ref61","doi-asserted-by":"crossref","first-page":"6103","DOI":"10.1038\/s41467-021-26401-w","article-title":"Molecular insights into receptor binding of recent emerging SARS-CoV-2 variants","volume":"12","author":"Han","year":"2021","journal-title":"Nat Commun"},{"key":"2026050905114633200_ref62","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1056\/NEJMc2031364","article-title":"Persistence and evolution of SARS-CoV-2 in an immunocompromised host","volume":"383","author":"Choi","year":"2020","journal-title":"N Engl J Med"},{"key":"2026050905114633200_ref63","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1016\/j.cell.2021.03.027","article-title":"SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralization escape mechanisms","volume":"184","author":"Clark","year":"2021","journal-title":"Cell"},{"key":"2026050905114633200_ref64","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.3201\/eid2710.211538","article-title":"Emergence of SARS-COV-2 spike protein escape mutation Q493R after treatment for COVID-19","volume":"27","author":"Focosi","year":"2021","journal-title":"Emerg Infect Dis"},{"key":"2026050905114633200_ref65","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.jinf.2021.08.033","article-title":"Emergence of Q493R mutation in SARS-CoV-2 spike protein during bamlanivimab\/etesevimab treatment and resistance to viral clearance","volume":"84","author":"Guigon","year":"2022","journal-title":"J Infect"},{"key":"2026050905114633200_ref66","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.abf9302","article-title":"Prospective mapping of viral mutations that escape antibodies used to treat COVID-19","volume":"371","author":"Starr","year":"2021","journal-title":"Science"},{"key":"2026050905114633200_ref67","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41392-020-00402-5","article-title":"RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response","volume":"5","author":"Liu","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"2026050905114633200_ref68","article-title":"Recombinant receptor-binding domains of multiple Middle East respiratory syndrome coronaviruses (MERS-CoVs) induce cross-neutralizing antibodies against divergent human and camel MERS-CoVs and antibody escape mutants","volume":"91","author":"Tai","year":"2016","journal-title":"J Virol"},{"key":"2026050905114633200_ref69","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2020.197863","article-title":"Characterization of novel monoclonal antibodies against MERS-coronavirus spike protein","volume":"278","author":"Goo","year":"2020","journal-title":"Virus Res"},{"key":"2026050905114633200_ref70","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/22221751.2020.1713705","article-title":"Polymorphisms in dipeptidyl peptidase 4 reduce host cell entry of Middle East respiratory syndrome coronavirus","volume":"9","author":"Kleine-Weber","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"2026050905114633200_ref71","doi-asserted-by":"crossref","first-page":"E2018","DOI":"10.1073\/pnas.1402074111","article-title":"Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution","volume":"111","author":"Tang","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026050905114633200_ref72","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nature12328","article-title":"Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26","volume":"500","author":"Lu","year":"2013","journal-title":"Nature"},{"key":"2026050905114633200_ref73","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/S0014-5793(99)01166-7","article-title":"Two highly conserved glutamic acid residues in the predicted beta propeller domain of dipeptidyl peptidase IV are required for its enzyme activity","volume":"458","author":"Abbott","year":"1999","journal-title":"FEBS Lett"},{"key":"2026050905114633200_ref74","doi-asserted-by":"crossref","first-page":"2212415","DOI":"10.1080\/19420862.2023.2212415","article-title":"Multivalent IgM scaffold enhances the therapeutic potential of variant-agnostic ACE2 decoys against SARS-CoV-2","volume":"15","author":"Verstraete","year":"2023","journal-title":"MAbs"},{"key":"2026050905114633200_ref75","doi-asserted-by":"crossref","first-page":"e369","DOI":"10.1016\/S2666-5247(23)00011-3","article-title":"Advances in developing ACE2 derivatives against SARS-CoV-2","volume":"4","author":"Zhang","year":"2023","journal-title":"Lancet Microbe"},{"key":"2026050905114633200_ref76","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1111\/pbi.12441","article-title":"Anti-infective immunoadhesins from plants","volume":"13","author":"Wycoff","year":"2015","journal-title":"Plant Biotechnol J"},{"key":"2026050905114633200_ref77","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/2042098611406318","article-title":"Immunogenicity and other problems associated with the use of biopharmaceuticals","volume":"2","author":"Tovey","year":"2011","journal-title":"Ther Adv Drug Saf"},{"key":"2026050905114633200_ref78","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40259-016-0174-5","article-title":"Assessing the immunogenicity of biopharmaceuticals","volume":"30","author":"Pineda","year":"2016","journal-title":"BioDrugs"},{"key":"2026050905114633200_ref79","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nature14264","article-title":"AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges","volume":"519","author":"Gardner","year":"2015","journal-title":"Nature"},{"key":"2026050905114633200_ref80","article-title":"Profiling the biophysical developability properties of common IgG1 Fc effector silencing variants","volume":"12","author":"Pejchal","year":"2023","journal-title":"Antibodies (Basel)"}],"container-title":["Antibody Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/abt\/advance-article-pdf\/doi\/10.1093\/abt\/tbad030\/55676177\/tbad030.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/abt\/article-pdf\/7\/1\/53\/56682702\/tbad030.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/abt\/article-pdf\/7\/1\/53\/56682702\/tbad030.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T09:12:00Z","timestamp":1778317920000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/abt\/article\/7\/1\/53\/7470454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,12]]},"references-count":80,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,16]]}},"URL":"https:\/\/doi.org\/10.1093\/abt\/tbad030","relation":{},"ISSN":["2516-4236"],"issn-type":[{"value":"2516-4236","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1]]},"published":{"date-parts":[[2023,12,12]]}}}